India · Delayed Price · Currency is INR Bacil Pharma Statistics
Total Valuation
Bacil Pharma has a market cap or net worth of INR 583.45 million. The enterprise value is 577.76 million.
| Market Cap | 583.45M |
| Enterprise Value | 577.76M |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bacil Pharma has 14.35 million shares outstanding. The number of shares has increased by 121.94% in one year.
| Current Share Class | 14.35M |
| Shares Outstanding | 14.35M |
| Shares Change (YoY) | +121.94% |
| Shares Change (QoQ) | +8.12% |
| Owned by Insiders (%) | 61.59% |
| Owned by Institutions (%) | n/a |
| Float | 5.44M |
Valuation Ratios
The trailing PE ratio is 36.62.
| PE Ratio | 36.62 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.35 |
| P/TBV Ratio | 2.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 81.99 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 37.14 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.68
| Current Ratio | 0.68 |
| Quick Ratio | 0.68 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 6.19% and return on invested capital (ROIC) is -1.00%.
| Return on Equity (ROE) | 6.19% |
| Return on Assets (ROA) | -0.58% |
| Return on Invested Capital (ROIC) | -1.00% |
| Return on Capital Employed (ROCE) | -0.99% |
| Weighted Average Cost of Capital (WACC) | 6.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | 7.78M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -5.65M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.88% in the last 52 weeks. The beta is 0.33, so Bacil Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +7.88% |
| 50-Day Moving Average | 52.91 |
| 200-Day Moving Average | 43.89 |
| Relative Strength Index (RSI) | 33.09 |
| Average Volume (20 Days) | 207,540 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.45M |
| Pretax Income | 9.90M |
| Net Income | 15.56M |
| EBITDA | -2.44M |
| EBIT | -2.45M |
| Earnings Per Share (EPS) | 1.11 |
Balance Sheet
The company has 5.69 million in cash and n/a in debt, with a net cash position of 5.69 million or 0.40 per share.
| Cash & Cash Equivalents | 5.69M |
| Total Debt | n/a |
| Net Cash | 5.69M |
| Net Cash Per Share | 0.40 |
| Equity (Book Value) | 248.13M |
| Book Value Per Share | 17.56 |
| Working Capital | -8.27M |
Cash Flow
| Operating Cash Flow | 7.12M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 7,000 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bacil Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -121.94% |
| Shareholder Yield | -121.94% |
| Earnings Yield | 2.67% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |